Biogen Inc. has disclosed uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists with improved brain penetration reported to be useful for the treatment of multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback